Publications
3 shownAtezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 3
- Citations
- 8,976
- Institution
- The University of Texas MD Anderson Cancer Center
External Links
Identifiers
- ORCID
- 0000-0002-9491-0587
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.